Charles Schwab Investment Management Inc. Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Charles Schwab Investment Management Inc. boosted its holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 3.7% in the third quarter, according to its most recent filing with the SEC. The institutional investor owned 250,346 shares of the specialty pharmaceutical company's stock after buying an additional 8,869 shares during the period. Charles Schwab Investment Management Inc. owned 1.19% of ANI Pharmaceuticals worth $14,936,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Dimensional Fund Advisors LP boosted its stake in ANI Pharmaceuticals by 3.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 630,226 shares of the specialty pharmaceutical company's stock worth $40,132,000 after purchasing an additional 21,053 shares during the period. Pacer Advisors Inc. boosted its position in shares of ANI Pharmaceuticals by 23,259.8% during the third quarter. Pacer Advisors Inc. now owns 568,343 shares of the specialty pharmaceutical company's stock worth $33,907,000 after acquiring an additional 565,910 shares during the last quarter. Global Alpha Capital Management Ltd. grew its stake in ANI Pharmaceuticals by 1.8% during the third quarter. Global Alpha Capital Management Ltd. now owns 536,450 shares of the specialty pharmaceutical company's stock valued at $32,005,000 after acquiring an additional 9,500 shares in the last quarter. Thompson Siegel & Walmsley LLC increased its holdings in ANI Pharmaceuticals by 17.6% in the 3rd quarter. Thompson Siegel & Walmsley LLC now owns 230,159 shares of the specialty pharmaceutical company's stock valued at $13,731,000 after acquiring an additional 34,416 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in ANI Pharmaceuticals by 1,005.8% in the 2nd quarter. Millennium Management LLC now owns 230,079 shares of the specialty pharmaceutical company's stock worth $14,651,000 after purchasing an additional 209,272 shares in the last quarter. 76.05% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ANIP. Raymond James raised their price objective on ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an "outperform" rating in a research report on Wednesday, September 18th. HC Wainwright reaffirmed a "buy" rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Piper Sandler assumed coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an "overweight" rating and a $68.00 price objective for the company. StockNews.com downgraded shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Finally, Truist Financial increased their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $77.33.

Insider Buying and Selling

In other ANI Pharmaceuticals news, CEO Nikhil Lalwani sold 33,481 shares of ANI Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $57.99, for a total value of $1,941,563.19. Following the completion of the transaction, the chief executive officer now owns 370,378 shares of the company's stock, valued at approximately $21,478,220.22. The trade was a 8.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 33,981 shares of company stock valued at $1,970,066 over the last quarter. 12.70% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

Shares of NASDAQ ANIP traded up $0.98 during midday trading on Friday, reaching $56.97. The company had a trading volume of 403,212 shares, compared to its average volume of 265,180. ANI Pharmaceuticals, Inc. has a 1 year low of $48.20 and a 1 year high of $70.81. The business's 50-day simple moving average is $58.05 and its 200 day simple moving average is $60.43. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The stock has a market cap of $1.20 billion, a P/E ratio of -103.58 and a beta of 0.73.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last issued its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. The company had revenue of $148.30 million during the quarter, compared to analyst estimates of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's quarterly revenue was up 12.5% on a year-over-year basis. During the same quarter last year, the business posted $1.05 EPS. On average, analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current fiscal year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.